menu
    • menu
    [{"orgOrder":0,"company":"Association Asthma, Bulgaria","sponsor":"Nasaleze","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BULGARIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Xylometazoline","moa":"Adrenergic receptor alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Association Asthma, Bulgaria","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Association Asthma, Bulgaria \/ Nasaleze","highestDevelopmentStatusID":"11","companyTruncated":"Association Asthma, Bulgaria \/ Nasaleze"},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Xylometazoline","moa":"Adrenergic receptor alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"McNeil AB \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Xylometazoline

    Menu

    Xylometazoline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            McNeil AB

                            Sweden arrow
                            Florida Innovation
                            Not Confirmed

                            McNeil AB

                            Sweden arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xylometazoline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Cong...

                            Details : Xylometazoline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Nasal Obstruction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2018

                            Lead Product(s) : Xylometazoline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Association Asthma, Bulgaria

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Association Asthma, Bulgaria

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xylometazoline

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Nasaleze

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            4"S" - Seasonal Symptoms Suppression Study

                            Details : Xylometazoline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2015

                            Lead Product(s) : Xylometazoline

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Nasaleze

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth